ARDX Ardelyx, Inc.

Note: The stock trades discussed in this article come from AI Finance Labs, an investment experiment that operates publicly viewable portfolios directed by models including Claude, ChatGPT, Grok and DeepSeek. Anthropic’s Claude AI recently sold its positions in Ardelyx Inc. (NASDAQ: ARDX) and Aris Mining Corp. (NYSE: ARIS) and replaced them with Syndax Pharmaceuticals Inc. […]

Ardelyx (NASDAQ:ARDX) expects to generate close to $500 million in revenue this year and reach profitability in 2027, supported by continued growth of its IBS-C treatment IBSRELA and hyperphosphatemia treatment XPHOZAH, executives said at a Morgan Stanley event. Chief Executive Officer Mike Raab sa

Ardelyx (ARDX) recently cut its 2026 IBSRELA revenue guidance to a range of $350 million to $370 million, down from $410 million to $430 million, citing tougher payer utilization-management hurdles that slowed new patient starts. See our latest analysis for Ardelyx. The guidance cut and lowered expectations for IBSRELA have come alongside a sharp reset in Ardelyx’s share price, with the stock down 23.43% on a 30 day share price return basis and 36.33% on a 1 year total shareholder return...

Record revenue masks payer headwinds forcing IBSRELA guidance cuts.

In August 2026, Ardelyx, Inc. reported second-quarter 2026 results showing revenue of US$120.88 million versus US$97.66 million a year earlier, with net loss narrowing to US$16.72 million and basic loss per share improving to US$0.07 from US$0.08. Alongside its results, Ardelyx updated full-year 2026 guidance, lifting expected IBSRELA revenue to US$350 million–US$370 million while keeping XPHOZAH revenue guidance steady at US$110 million–US$120 million, giving investors a clearer view of how...

Ardelyx (ARDX) is back in focus after reporting record Q2 2026 revenue driven by IBSRELA and XPHOZAH, while missing earnings estimates and trimming IBSRELA guidance because of payer related hurdles. See our latest analysis for Ardelyx. Despite the record Q2 revenue, Ardelyx’s recent earnings miss and reduced IBSRELA guidance appear to be weighing on sentiment, with the share price down 9.48% over 30 days and 20.81% year to date, even though the 5 year total shareholder return of 220.39%...

ARDX, ARDT and GPRE have been added to the Zacks Rank #5 (Strong Sell) List on August 7th, 2026.

Ardelyx Inc (ARDX) delivers 31% revenue growth in Q2 2026 while navigating payer-imposed challenges that led to a lowered Ibsrela outlook and withdrawal of Xphozah guidance.

Ardelyx (ARDX) delivered earnings and revenue surprises of -40.00% and -2.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

While the top- and bottom-line numbers for Ardelyx (ARDX) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Ardelyx (NASDAQ:ARDX) reported second-quarter product revenue of $118 million, up 31% from a year earlier and representing the company’s largest quarterly revenue total to date. The company lowered its 2026 revenue outlook for IBSRELA while maintaining its forecast for XPHOZAH, citing increased paye

Indivior Pharmaceuticals Inc. (INDV) delivered earnings and revenue surprises of +18.56% and +11.36%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ARDX, BDORY and AXSM have been added to the Zacks Rank #5 (Strong Sell) List on July 29, 2026.

ABR, ARDX and RGNX have been added to the Zacks Rank #5 (Strong Sell) List on July 23, 2026.

Ardelyx, Inc (NASDAQ:ARDX) is a biotech company. It makes drugs for gut and kidney conditions. Its main drug is Ibsrela, a treatment for IBS with constipation, and its second drug is Xphozah, which lowers phosphate levels in dialysis patients. Claude is bullish on the stock because the price has not caught up to the company’s […]